PPI-668

DRUG3 trials

Sponsors

Presidio Pharmaceuticals, Inc.

Conditions

Chronic Hepatitis CHepatitis C, ChronicPharmacokinetic Assessments in Healthy Volunteers

Phase 1

A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1

CompletedNCT01448200

Presidio Pharmaceuticals, Inc.Hepatitis C, Chronic

Start: 2011-10-31End: 2012-11-30Updated: 2012-11-16

A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole

CompletedNCT01786382

Presidio Pharmaceuticals, Inc.Pharmacokinetic Assessments in Healthy Volunteers

Start: 2013-02-28End: 2013-03-31Updated: 2013-03-26

Phase 2

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

CompletedNCT01859962

Presidio Pharmaceuticals, Inc.Chronic Hepatitis C

Start: 2013-05-31End: 2014-12-31Updated: 2015-11-25